keyword
MENU ▼
Read by QxMD icon Read
search

Free psa

keyword
https://www.readbyqxmd.com/read/28230003/risk-stratification-for-disease-progression-in-pt3-prostate-cancer-after-robot-assisted-radical-prostatectomy
#1
Jeong Hee Hong, Young Suk Kwon, Isaac Yi Kim
The aim of this study is to identify optimal patients for adjuvant radiation therapy (ART) in pT3 prostate cancer. The role of ART for patients with adverse pathologic features after radical prostatectomy (RP) has been demonstrated, but over- or under-treatment remains a significant concern. Two-hundred and five patients with pT3N0M0 who underwent robot-assisted RP without ART were analyzed. Multivariate Cox proportional regression analyses were used to identify predictors of biochemical recurrence (BCR) and clinical progression (CP)...
February 21, 2017: Asian Journal of Andrology
https://www.readbyqxmd.com/read/28226496/nano-fabricated-memristive-biosensors-for-biomedical-applications-with-liquid-and-dried-samples
#2
I Tzouvadaki, X Lu, G De Micheli, S Ingebrandt, S Carrara, I Tzouvadaki, X Lu, G De Micheli, S Ingebrandt, S Carrara, I Tzouvadaki, X Lu, S Ingebrandt, G De Micheli, S Carrara
Nanowire based platforms are widely reported for sensing applications and for their potential in the bio-detection field. In the present work, memristive nanowire devices are implemented for label-free sensing in liquid samples as well as in dried samples via leveraging the modification of the hysteresis in the devices electrical response as a consequence of the surface modification. First, pH sensing in liquid conditions is demonstrated. In addition, the memristive devices are bio-functionalized using antibodies for Prostate Specific Antigen (PSA) as case of study...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28225313/efficacy-and-safety-of-a-new-topical-testosterone-replacement-gel-therapy-for-the-treatment-of-male-hypogonadism
#3
Glenn Cunningham, Laurence Belkoff, Gerald Brock, Mitchell Efros, Marc Gittelman, Dario Carrara, Anders Neijber, Masakazu Ando, Jules Mitchel
OBJECTIVE: Testosterone replacement therapy is indicated for male hypogonadism. This study aimed to evaluate the efficacy and safety of Testosterone gel 2% (Tgel) over 90-days. METHODS: This phase 3, open-label, non-comparator study was conducted in adult hypogonadal men (two consecutive fasting serum testosterone values <300 ng/dL and >86% subjects with symptoms consistent with testosterone deficiency). Subjects applied Tgel 23 mg/day (single pump-actuation using hands-free cap applicator)...
February 22, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28222672/long-leukocyte-telomere-length-in-prostate-cancer-patients-at-diagnosis-is-associated-with-poor-metastasis-free-and-cancer-specific-survival
#4
Ulrika Svenson, Göran Roos, Pernilla Wikström
Previous studies have suggested that leukocyte telomere length is associated with risk of developing prostate cancer. Investigations of leukocyte telomere length as a prognostic factor in prostate cancer are, however, lacking. In this study, leukocyte telomere length was investigated both as a risk marker, comparing control subjects and patient risk groups (based on serum levels of prostate-specific antigen, tumor differentiation, and tumor stage), and as a prognostic marker for metastasis-free and cancer-specific survival...
February 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28220449/current-management-strategy-for-active-surveillance-in-prostate-cancer
#5
REVIEW
Jamil S Syed, Juan Javier-Desloges, Stephanie Tatzel, Ansh Bhagat, Kevin A Nguyen, Kevin Hwang, Sarah Kim, Preston C Sprenkle
PURPOSE OF REVIEW: Active surveillance has been increasingly utilized as a strategy for the management of favorable-risk, localized prostate cancer. In this review, we describe contemporary management strategies of active surveillance, with a focus on traditional stratification schemes, new prognostic tools, and patient outcomes. RECENT FINDINGS: Patient selection, follow-up strategy, and indication for delayed intervention for active surveillance remain centered around PSA, digital rectal exam, and biopsy findings...
February 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28215847/prostate-cancer-screening-in-men-aged-50-to-69-years-sthlm3-a-prospective-population-based-diagnostic-study-gr%C3%A3-nberg-h-adolfsson-j-aly-m-nordstr%C3%A3-m-t-wiklund-p-brandberg-y-thompson-j-wiklund-f-lindberg-j-clements-m-egevad-l-eklund-m-lancet-oncol-2015-dec-16
#6
Eggener Scott, J Adolfsson, M Aly, T Nordström, P Wiklund, Y Brandberg, J Thompson, F Wiklund, J Lindberg, M Clements, L Egevad, M Eklund
BACKGROUND: The prostate-specific antigen (PSA) test is used to screen for prostate cancer but has a high false-positive rate that translates into unnecessary prostate biopsies and overdiagnosis of low-risk prostate cancers. We aimed to develop and validate a model to identify high-risk prostate cancer (with a Gleason score of at least 7) with better test characteristics than that provided by PSA screening alone. METHODS: The Stockholm 3 (STHLM3) study is a prospective, population-based, paired, screen-positive, diagnostic study of men without prostate cancer aged 50 to 69 years randomly invited by date of birth from the Swedish Population Register kept by the Swedish Tax Agency...
March 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28215654/dendritic-cell-vaccination-in-combination-with-docetaxel-for-patients-with-metastatic-castration-resistant-prostate-cancer-a-randomized-phase-ii-study
#7
Per Kongsted, Troels Holz Borch, Eva Ellebaek, Trine Zeeberg Iversen, Rikke Andersen, Özcan Met, Morten Hansen, Henriette Lindberg, Lisa Sengeløv, Inge Marie Svane
BACKGROUND AIMS: We investigated whether the addition of an autologous dendritic cell-based cancer vaccine (DCvac) induces an immune response in patients with metastatic castration-resistant prostate cancer treated with docetaxel. METHODS: Forty-three patients were randomized 1:1 to receive up to 10 cycles of docetaxel alone, 75 mg/m(2) every 3 weeks or in combination with DCvac. Monocytes were harvested following a leukapheresis procedure, matured ex vivo and subsequently transfected with messenger RNA encoding multiple tumor-associated antigens (TAAs)...
February 15, 2017: Cytotherapy
https://www.readbyqxmd.com/read/28213802/high-expression-of-aspm-correlates-with-tumor-progression-and-predicts-poor-outcome-in-patients-with-prostate-cancer
#8
Jian-Jiang Xie, Yang-Jia Zhuo, Yu Zheng, Ru-Jun Mo, Ze-Zhen Liu, Bo-Wei Li, Zhi-Duan Cai, Xue-Jin Zhu, Yu-Xiang Liang, Hui-Chan He, Wei-de Zhong
PURPOSE: Abnormal spindle microtubule assembly (ASPM) gene was known to be linked with poor clinical prognosis in various tumors. However, the clinical significance of ASPM in prostate cancer (PCa) has not yet been understood. The purpose of this study was to determine the association of ASPM with tumor progression and prognosis in PCa patients. METHODS: The expression of ASPM at protein level in human PCa and non-cancerous prostate tissue was detected by immunohistochemical analysis, which was further validated by using microarray-based dataset (NCBI GEO: GSE21032 and The Cancer Genome Atlas (TCGA) dataset) at mRNA level...
February 17, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28212119/the-role-of-biomarkers-in-undiagnosed-men
#9
Hasan Dani, Stacy Loeb
PURPOSE OF REVIEW: This article intends to review biomarkers derived from blood, urine, and tissue that can aid in the diagnosis of prostate cancer (PCa). RECENT FINDINGS: PCa screening requires tools that complement prostate-specific antigen (PSA) with a higher specificity for clinically significant disease. Novel blood biomarkers, such as the Prostate Health Index (phi) and 4Kscore, utilize isoforms of PSA to more accurately predict high-grade PCa than traditional tools such as PSA and the percentage free-to-total PSA...
February 16, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28197033/biochemical-failure-after-radical-prostatectomy-in-intermediate-risk-group-men-increases-with-the-number-of-risk-factors
#10
Nobuki Furubayashi, Takahito Negishi, Hidenori Iwai, Kei Nagase, Kenichi Taguchi, Mototsugu Shimokawa, Motonobu Nakamura
INTRODUCTION: We aimed to determine whether the number and type of risk factors are associated with biochemical recurrence-free survival after radical prostatectomy in men with D'Amico intermediate-risk prostate cancer. MATERIALS AND METHODS: Between August 1998 and May 2013, 481 Japanese patients underwent antegrade radical prostatectomy. The relationships between the rate of PSA failure after radical prostatectomy and the number and type of risk factors were examined in the intermediate-risk group...
January 2017: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/28193072/semiautomated-support-photoelectrochemical-immunosensing-platform-for-portable-and-high-throughput-immunoassay-based-on-au-nanocrystal-decorated-specific-crystal-facets-bivo4-photoanode
#11
Jian Shu, Zhenli Qiu, Zhenzhen Lin, Guoneng Cai, Huanghao Yang, Dianping Tang
Photoelectrochemical (PEC) measurement has been developed rapidly for bioanalysis in recent years. However, the actual application for most existed PEC bioanalytical systems is still a challenge because the perfect solutions for sensing surface design, high-throughput detection, and portability are lacked. To successfully overcome these limitations and realize accurate, continuous screening and assessing on prognostic indicator of early stage cancer on the spot, an innovative and portable semiautomated support power-free photoelectrochemical (SP-PEC) immunosensing platform consisted with a miniature semiautomatic injection system and digital multimeter (DMM) readout is designed (prostate specific antigen, PSA, was used as the proof-of-concept analyte)...
December 20, 2016: Analytical Chemistry
https://www.readbyqxmd.com/read/28190704/high-risk-prostate-cancer-and-radiotherapy-the-past-and-the-future-a-benchmark-for-a-new-mixed-beam-radiotherapy-approach
#12
Giulia Marvaso, Barbara A Jereczek-Fossa, Giulia Riva, Camilla Bassi, Cristiana Fodor, Delia Ciardo, Raffaella Cambria, Floriana Pansini, Dario Zerini, Paolo De Marco, Federica Cattani, Ottavio De Cobelli, Roberto Orecchia
BACKGROUND: The prognosis for patients with high-risk prostate cancer is poor. No consensus exists on the most effective treatment. The aim of this retrospective study was to identify the biochemical progression-free survival and the toxicity profile of patients with localized high-risk prostate cancer treated with external beam radiation therapy. These results will constitute a benchmark for a prospective "mixed beam" trial: a boost with carbon ions followed by a pelvic photon intensity-modulated radiotherapy (NCT02672449 [clinicaltrials...
January 18, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28188090/independent-association-between-time-to-prostate-specific-antigen-psa-nadir-and-psa-progression-free-survival-in-patients-with-docetaxel-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer-receiving-abiraterone-acetate-but-not-enzalutamide
#13
Hideaki Miyake, Takuto Hara, Keita Tamura, Takayuki Sugiyama, Hiroshi Furuse, Seiichiro Ozono, Masato Fujisawa
PURPOSE: The objective of this study was to compare the prognostic effect of time to prostate-specific antigen (PSA) nadir (TTPN) after treatment with abiraterone acetate (AA) and enzalutamide (Enz) in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer (mCRPC). METHODS: This study included a total of 297 consecutive patients with mCRPC, of whom 125 and 172 received AA and Enz, respectively, without previous treatment with docetaxel and subsequently achieved any degree of PSA reduction after the administration of either agent...
February 7, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28185875/salvage-stereotactic-body-radiotherapy-for-isolated-lymph-node-recurrent-prostate-cancer-single-institution-series-of-94-consecutive-patients-and-124-lymph-nodes
#14
Barbara Alicja Jereczek-Fossa, Giuseppe Fanetti, Cristiana Fodor, Delia Ciardo, Luigi Santoro, Claudia Maria Francia, Matteo Muto, Alessia Surgo, Dario Zerini, Giulia Marvaso, Giorgia Timon, Paola Romanelli, Elena Rondi, Stefania Comi, Federica Cattani, Federica Golino, Stefano Mazza, Deliu Victor Matei, Matteo Ferro, Gennaro Musi, Franco Nolè, Ottavio de Cobelli, Piet Ost, Roberto Orecchia
BACKGROUND: The purpose of the study was to evaluate the prostate serum antigen (PSA) response, local control, progression-free survival (PFS), and toxicity of stereotactic body radiotherapy (SBRT) for lymph node (LN) oligorecurrent prostate cancer. PATIENTS AND METHODS: Between May 2012 and October 2015, 124 lesions were treated in 94 patients with a median dose of 24 Gy in 3 fractions. Seventy patients were treated for a single lesion and 25 for > 1 lesion...
January 11, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28185762/biochemical-control-and-toxicity-for-favorable-and-intermediate-risk-patients-using-real-time-intraoperative-inverse-optimization-prostate-seed-implant-less-is-more
#15
G Shukla, A Sarkar, A Hanlon, E Crockett, H C Chen, J Martelli-Raben, A Glick, B Benge, M Lobis, S Terranova, T Desperito, D Cozzolino, E Kemmerer, F Mourtada, A Raben
PURPOSE: To report the biochemical control rate and clinical outcomes with real-time inverse planning (inverse optimization prostate seed implant [IO-PSI]) for favorable-risk (FR) and intermediate-risk (IR) prostate adenocarcinoma in a community practice setting. This analysis is an extended followup of our initial report, with favorable early biochemical control rate (biochemical nonevidence of disease) of 97% at 4 years. METHODS AND MATERIALS: Three hundred fifty-seven evaluable patients with FR and IR prostate cancer underwent real-time IO-PSI (iodine-125/145 Gy or palladium-103/120 Gy) between 2001 and 2013...
February 6, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28179099/hydrophobically-modified-polysaccharide-based-on-polysialic-acid-nanoparticles-as-carriers-for-anticancer-drugs
#16
Bom Jung, Man-Kyu Shim, Min-Ju Park, Eun Hyang Jang, Hong Yeol Yoon, Kwangmeyung Kim, Jong-Ho Kim
This study presented the development of hydrophobically modified polysialic acid (HPSA) nanoparticles, a novel anticancer drug nanocarrier that increases therapeutic efficacy without causing nonspecific toxicity towards normal cells. HPSA nanoparticles were prepared by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC)/N-hydroxysuccinimide (NHS) coupling between N-deacetylated polysialic acid (PSA) and 5β-cholanic acid. The physicochemical characteristics of HPSA nanoparticles (zeta-potential, morphology and size) were measured, and in vitro cytotoxicity and cellular uptake of PSA and HPSA nanoparticles were tested in A549 cells...
February 4, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28171710/clinical-outcomes-and-survival-surrogacy-studies-of-prostate-specific-antigen-declines-following-enzalutamide-in-men-with-metastatic-castration-resistant-prostate-cancer-previously-treated-with-docetaxel
#17
Andrew J Armstrong, Fred Saad, De Phung, Carl Dmuchowski, Neal D Shore, Karim Fizazi, Mohammad Hirmand, David Forer, Howard I Scher, Johann De Bono
BACKGROUND: In the AFFIRM trial, enzalutamide significantly increased overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) after chemotherapy versus placebo and significantly decreased prostate-specific antigen (PSA) levels. The goal of this post hoc analysis was to associate levels of PSA decline from baseline after enzalutamide with clinical outcomes in the postchemotherapy mCRPC setting. METHODS: Men in the AFFIRM trial (n = 1199) were grouped by maximal PSA decline in the first 90 days of treatment...
February 7, 2017: Cancer
https://www.readbyqxmd.com/read/28161841/prognostic-factors-of-first-line-docetaxel-treatment-in-castration-resistant-prostate-cancer-roles-of-neutrophil-to-lymphocyte-ratio-in-patients-from-northwestern-china
#18
Xin-Qi Pei, Da-Lin He, Ge Tian, Wei Lv, Yu-Mei Jiang, Da-Peng Wu, Jin-Hai Fan, Kai-Jie Wu
OBJECTIVE: To evaluate the potential role of neutrophil-to-lymphocyte ratio (NLR) with therapeutic response in patients who were treated with docetaxel for mCRPC. MATERIALS AND METHODS: We retrospectively analyzed the clinical data from 111 consecutive patients who were treated with docetaxel for mCRPC from 2009 to 2016 in a single center from Northwestern China. Pretreatment baseline and follow-up data including age, PSA response, Gleason score, and cycle number were reviewed, and multivariable Cox regression models and Kaplan-Meier analysis were used to predict overall survival (OS) and progression-free survival (PFS)...
February 4, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28161323/a-multicenter-phase-i-study-of-cabazitaxel-mitoxantrone-and-prednisone-for-chemotherapy-na%C3%A3-ve-patients-with-metastatic-castration-resistant-prostate-cancer-a-department-of-defense-prostate-cancer-clinical-trials-consortium-study
#19
Rahul Aggarwal, Alan Bryce, Charles J Ryan, Andrea Harzstark, Christina Derleth, Won Kim, Terence Friedlander, Amy M Lin, Tammy Rodvelt-Bagchi, Mallika Dhawan, Li Zhang, Mina Lee, Eric Siebeneck, Jeffrey Hough, Eric J Small
BACKGROUND: Cabazitaxel plus prednisone has significant activity in patients with chemotherapy-naïve and pretreated metastatic castration-resistant prostate cancer (mCRPC). Mitoxantrone has antitumor activity in mCRPC and nonoverlapping mechanism of action and toxicity profile. OBJECTIVE: To establish the maximally tolerated dose of the combination of cabazitaxel, mitoxantrone, and prednisone. METHODS AND MATERIALS: Patients with chemotherapy-naïve mCRPC were prospectively enrolled in a multicenter phase 1 trial...
February 1, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28160568/serum-ferritin-in-combination-with-prostate-specific-antigen-improves-predictive-accuracy-for-prostate-cancer
#20
Xijuan Wang, Peng An, Jiling Zeng, Xiaoyan Liu, Bo Wang, Xuexian Fang, Fudi Wang, Guoping Ren, Junxia Min
Ferritin is highly expressed in many cancer types. Although a few studies have reported an association between high serum ferritin levels and an increased risk of prostate cancer, the results are inconsistent. Therefore, we performed a large case-control study consisting of 2002 prostate cancer patients and 951 control patients with benign prostatic hyperplasia (BPH). We found that high ferritin levels were positively associated with increased serum prostate-specific antigen (PSA) levels and prostate cancer risk; each 100 ng/ml increase in serum ferritin increased the odds ratio (OR) by 1...
February 1, 2017: Oncotarget
keyword
keyword
25554
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"